Literature DB >> 21886577

Association Analysis of Nuclear Receptor Rev-erb Alpha Gene (NR1D1) and Japanese Methamphetamine Dependence.

Taro Kishi1, Tsuyoshi Kitajima, Kunihiro Kawashima, Tomo Okochi, Yoshio Yamanouchi, Yoko Kinoshita, Hiroshi Ujike, Toshiya Inada, Mitsuhiko Yamada, Naohisa Uchimura, Ichiro Sora, Masaomi Iyo, Norio Ozaki, Nakao Iwata.   

Abstract

Several investigations suggested abnormalities in circadian rhythms are related to the pathophysiology of psychiatric disorders, including drug addiction. Recently, orphan nuclear receptor rev-erb alpha and glycogen synthase kinase-3 β (GSK-3β) were shown to be important circadian components. In addition, the orphan nuclear receptor rev-erb alpha is a key negative feedback regulator of the circadian clock. These evidences indicate that rev-erb alpha gene (NR1D1) is a good candidate gene for the pathogenesis of methamphetamine dependence. To evaluate the association between NR1D1 and methamphetamine dependence, we conducted a case-control study of Japanese samples (215 methamphetamine dependence and 232 controls) with three tagging SNPs selected by HapMap database. Written informed consent was obtained from each subject. This study was approved by the ethics committees at Fujita Health University, Nagoya University Graduate School of Medicine and each participating member of the Institute of the Japanese Genetics Initiative for Drug Abuse (JGIDA). We did not detect an association between NR1D1 and Japanese methamphetamine dependence patients in allele/genotype-wise analysis, or the haplotype analysis. Our findings suggest that NR1D1 does not play a major role in the pathophysiology of methamphetamine dependence in the Japanese population.

Entities:  

Keywords:  Orphan nuclear receptor Rev-erb alpha gene (NR1D1); linkage disequilibrium.; methamphetamine dependence; tagging SNPs

Year:  2011        PMID: 21886577      PMCID: PMC3137167          DOI: 10.2174/157015911795017065

Source DB:  PubMed          Journal:  Curr Neuropharmacol        ISSN: 1570-159X            Impact factor:   7.363


INTRODUCTION

Several investigation suggest that abnormalities in circadian rhythms may be involved in the pathophysiology of psychiatric disorders, including drug addiction [1-3]. The evidence for this relation is discussed in more detail in our previous papers and a review by Barnard and Nolan [4-7]. Recently, Mohawk and colleagues reported that mice which were arrhythmic due to a lack of circadian clock genes showed circadian locomotor rhythms when treated with methamphetamine [8]. If patients with drug addiction disorders had disrupted circadian rhythms, it is possible that taking methamphetamine helps to restore circadian rhythms of taking into methamphetamine to keep to circadian rhythm. Several animal studies have shown that methamphetamine increased expression of circadian clock molecule genes such as Per1, Per2, Bmal1, and Npas2 in the brain [9-11]. Recently, we detected the significant association between prokineticin 2 receptor gene (PROKR2), which is one of the clock genes, and Japanese methamphetamine dependence patients [12]. Recently, rev-erb alpha and glycogen synthase kinase-3 β (GSK-3β), which are known to be important circadian components [13], have been discussed in relation with lithium. Several studies have revealed that lithium affects circadian rhythms through GSK-3β [14-16]. Yin et al. showed that Rev-erb alpha is a target of GSK-3β kinase activity, needed to mediate this effect to regulate circadian rhythms [13]. These evidences indicate that rev-erb alpha gene (NR1D1) is a good candidate gene for the pathogenesis of methamphetamine dependence. To evaluate the association between NR1D1 and methamphetamine dependence, we conducted a case-control study of Japanese samples (215 methamphetamine dependence and 232 controls) with three tagging SNPs selected by HapMap database.

MATERIALS AND METHODS

Subjects

The subjects in the association analysis were 215 METH deprendence patients (175 males and 40 females; mean age ± standard deviation (SD) 36.3 ± 11.4 years) and 232 healthy controls (187 males and 45 females; 36.4 ± 11.3 years). The age and sex of the control subjects did not differ from those of the methamphetamine dependence patients. All subjects were unrelated to each other, ethnically Japanese, and lived in the central area of Japan. The patients were diagnosed according to DSM-IV criteria with consensus of at least two experienced psychiatrists on the basis of unstructured interviews and a review of medical records. One hundred ninety-seven of the subjects with METH dependence had a diagnosis of co-morbid METH induced psychosis. METH-induced psychosis patients were divided into two categories of psychosis prognosis, the transient type and the prolonged type, which showed remission of psychotic symptoms within 1 month and after more than 1 month, respectively, after the discontinuance of methamphetamine consumption and beginning of treatment with neuroleptics; 112 patients (56.9%) were the transient type, and 85 patients (42.1%) were the prolonged type. One hundred eighty-two subjects with METH-induced psychosis also had dependence on drugs other than METH. Cannabinoids were the most frequency abused drugs (21.4%), followed by cocaine (9.09%), LSD (9.09%), opioids (7.69%), and hypnotics (7.69%). Subjects with METH-induced psychosis were excluded if they had a clinical diagnosis of psychotic disorder, mood disorder, anxiety disorder or eating disorder. More detailed characterizations of these subjects have been published elsewhere [17, 18]. All healthy controls were also psychiatrically screened based on unstructured interviews. None had severe medical complications such as liver cirrhosis, renal failure, heart failure or other Axis-I disorders according to DSM-IV. The study was described to subjects and written informed consent was obtained from each. This study was approved by the Ethics Committee at Fujita Health University, Nagoya University School of Medicine and and each participating member of the Institute of the Japanese Genetics Initiative for Drug Abuse (JGIDA).

SNPs Selection and Linkage Disequilibrium (LD) Evaluation

We first consulted the HapMap database (release#20/phase II, Jan 2006, www.hapmap.org, population: Japanese Tokyo, minor allele frequencies (MAFs) of more than 0.05) and included 5 SNPs covering NR1D1 (5’-flanking regions including about 750 bp from the initial exon and about 1 kb downstream (3’) from the last exon: HapMap database contig number chr17: 35501880..35510616). Then three ‘tagging (tag) SNPs’ were selected with the criteria of r2 threshold greater than 0.8 in ‘pair-wise tagging only’ mode using the ‘Tagger’ program (Paul de Bakker, http://www/broad.mit.edu/mpg/tagger), in Haploview [19], three ‘tag SNPs’ (rs939347, rs2071427 and rs3744805) were selected for the following association analysis.

SNPs Genotyping

We used TaqMan assays (ABI: Applied Biosystems, Inc., Foster City, CA,) for all SNPs. One allelic probe was labeled with FAM dye and the other with the fluorescent VIC dye. The plates were heated for 2 min at 50°C and 95°C for 10 min, followed by 45 cycles of 95°C for 15 s and 58°C for 1 min. Please refer to ABI for the primer sequence. Detailed information is available on request.

Statistical Analysis

Genotype deviation from the Hardy-Weinberg equilibrium (HWE) was evaluated by chi-square test (SAS/Genetics, release 8.2, SAS Japan Inc, Tokyo, Japan). Marker-trait association analysis was used to evaluate allele- and genotype-wise association with the chi-square test (SAS/Genetics, release 8.2, SAS Japan Inc, Tokyo, Japan), and haplotype-wise association analysis was conducted with a likelihood ratio test using the COCAPHASE2.402 program [20]. We used the permutation test option as provided in the haplotype-wise analysis to avoid spurious results and correct for multiple testing. Permutation test correction was performed using 1000 iterations (random permutations). Power calculation was performed using a genetic power calculator [21]. The significance level for all statistical tests was 0.05.

RESULTS

The LD structure of NR1D1 from the HapMap database samples can be seen our previous paper [22]. Genotype frequencies of all SNPs were in HWE. We did not detect between all tagging SNPs and METH dependence in the Japanese population in the allele /genotype-wise (Table ) or haplotype-wise analysis (P haplotype= 0.775). In addition, we found no association between four tagging SNPs and METH-induced psychosis patients in the allele /genotype-wise (Table ) or haplotype-wise analysis (P haplotype= 0.699). In the power analysis, we obtained more than 80% power for the detection of association when we set the genotype relative risk at 1.63-1.86 in METH dependence for NR1D1 under a multiplicative model of inheritance

DISCUSSION

We did not find an association between NR1D1 and Japanese METH dependence and METH-induced psychosis patients. Therefore, we reasoned that NR1D1 may not play an important role in the pathophysiology of METH dependence and METH-induced psychosis in the Japanese population. However, because our samples are small, we considered that there is a possibility of statistical error in these results. Recently, we reported that NR1D1 was not associated with major depressive disorder and selective serotonin reuptake inhibitor response to major depressive disorder [7, 22]. On the other hand, we detected the associations between PROKR2 and not only mood disorders including major depressive disorder and bipolar disorder but also METH dependence and METH-induced psychosis in the Japanese population [12, 23]. We hypothesized that mood disorders and drug addiction have common susceptibility genes. A few points of caution should be mentioned with respect to our results. Firstly, the lack of association may be due to small sample size. Ideal samples for this study are METH use disorder samples with and without dependence and psychosis. Because we had only a few METH use disorder samples without dependence and psychosis, and we wanted to avoid statistical error, we did not perform an association analysis with these samples. Secondly, we did not include a mutation scan to detect rare variants. We designed the study based on the common disease-common variants hypothesis [24]. Further investigation will be required, such as medical resequencing using larger samples. However, statistical power is needed to evaluate the association of rare variants. To overcome these limitations, a replication study using larger samples or samples of other populations will be required for conclusive results [25]. In conclusion, our results suggest that NR1D1 may not play a role in the pathophysiology of METH dependence in the Japanese population. However, because we did not perform a mutation scan of NR1D1, a replication study using a larger sample may be required for conclusive results.
Table 1

Association Analysis of NRIDI with Methamphetamine Dependence and Methamphetamine-Induced Psychosis

SNP IDaPhenotypebMAFcNGenotype DistributiondP-Valuee
M/MM/mm/mHWEGenotypeAllele
rs939347Control0.48323259121520.502
A>GMETH dependence0.498215551062320.8380.7700.703
METH-induced psychosis0.48719751100460.8240.9560.944
rs2071427Control0.46923266114520.835
G>AMETH dependence0.45821565103470.4700.9180.726
METH-induced psychosis0.4521975998400.9520.8560.597
rs3744805Control0.48923262113570.699
A>GMETH dependence0.51621551106580.8500.7200.419
METH-induced psychosis0.5181974992560.3630.6590.405

major allele>minor allele

METH: methamphetamin

MAF: minor allele frequency

M: major allele, m: minor allele

Hardy-Weinberg equilibrium

  25 in total

Review 1.  Glycogen synthase kinase-3: a target for novel bipolar disorder treatments.

Authors:  Todd D Gould; Carlos A Zarate; Husseini K Manji
Journal:  J Clin Psychiatry       Date:  2004-01       Impact factor: 4.384

2.  Pedigree disequilibrium tests for multilocus haplotypes.

Authors:  Frank Dudbridge
Journal:  Genet Epidemiol       Date:  2003-09       Impact factor: 2.135

3.  Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits.

Authors:  S Purcell; S S Cherny; P C Sham
Journal:  Bioinformatics       Date:  2003-01       Impact factor: 6.937

4.  Association analysis of nuclear receptor Rev-erb alpha gene (NR1D1) with mood disorders in the Japanese population.

Authors:  Taro Kishi; Tsuyoshi Kitajima; Masashi Ikeda; Yoshio Yamanouchi; Yoko Kinoshita; Kunihiro Kawashima; Tomo Okochi; Norio Ozaki; Nakao Iwata
Journal:  Neurosci Res       Date:  2008-08-30       Impact factor: 3.304

5.  Methamphetamine-induced, suprachiasmatic nucleus-independent circadian rhythms of activity and mPer gene expression in the striatum of the mouse.

Authors:  Michihiko Iijima; Takato Nikaido; Masashi Akiyama; Takahiro Moriya; Shigenobu Shibata
Journal:  Eur J Neurosci       Date:  2002-09       Impact factor: 3.386

6.  Lithium activates the Wnt and phosphatidylinositol 3-kinase Akt signaling pathways to promote cell survival in the absence of soluble survival factors.

Authors:  Diviya Sinha; Zhiyong Wang; Kathleen L Ruchalski; Jerrold S Levine; Selvi Krishnan; Wilfred Lieberthal; John H Schwartz; Steven C Borkan
Journal:  Am J Physiol Renal Physiol       Date:  2004-11-30

7.  Orphan nuclear receptor Rev-erb alpha gene (NR1D1) and fluvoxamine response in major depressive disorder in the Japanese population.

Authors:  Taro Kishi; Tsuyoshi Kitajima; Masashi Ikeda; Yoshio Yamanouchi; Yoko Kinoshita; Kunihiro Kawashima; Tomo Okochi; Norio Ozaki; Nakao Iwata
Journal:  Neuropsychobiology       Date:  2009-07-02       Impact factor: 2.328

8.  Association study of clock gene (CLOCK) and schizophrenia and mood disorders in the Japanese population.

Authors:  Taro Kishi; Tsuyoshi Kitajima; Masashi Ikeda; Yoshio Yamanouchi; Yoko Kinoshita; Kunihiro Kawashima; Tomo Okochi; Takenori Okumura; Tomoko Tsunoka; Toshiya Inada; Norio Ozaki; Nakao Iwata
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-02-17       Impact factor: 5.270

9.  Serotonin 1A receptor gene is associated with Japanese methamphetamine-induced psychosis patients.

Authors:  Taro Kishi; Tomoko Tsunoka; Masashi Ikeda; Tsuyoshi Kitajima; Kunihiro Kawashima; Tomo Okochi; Takenori Okumura; Yoshio Yamanouchi; Yoko Kinoshita; Hiroshi Ujike; Toshiya Inada; Mitsuhiko Yamada; Naohisa Uchimura; Ichiro Sora; Masaomi Iyo; Norio Ozaki; Nakao Iwata
Journal:  Neuropharmacology       Date:  2009-09-10       Impact factor: 5.250

10.  Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade.

Authors:  Jean-Martin Beaulieu; Tatyana D Sotnikova; Wei-Dong Yao; Lisa Kockeritz; James R Woodgett; Raul R Gainetdinov; Marc G Caron
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-24       Impact factor: 11.205

View more
  1 in total

1.  Associations between the orexin (hypocretin) receptor 2 gene polymorphism Val308Ile and nicotine dependence in genome-wide and subsequent association studies.

Authors:  Daisuke Nishizawa; Shinya Kasai; Junko Hasegawa; Naomi Sato; Hidetaka Yamada; Fumihiko Tanioka; Makoto Nagashima; Ryoji Katoh; Yasuo Satoh; Megumi Tagami; Hiroshi Ujike; Norio Ozaki; Toshiya Inada; Nakao Iwata; Ichiro Sora; Masaomi Iyo; Mitsuhiko Yamada; Naoki Kondo; Moo-Jun Won; Nobuya Naruse; Kumi Uehara-Aoyama; Masanari Itokawa; Kazutaka Ohi; Ryota Hashimoto; Kumpei Tanisawa; Tomio Arai; Seijiro Mori; Motoji Sawabe; Makiko Naka-Mieno; Yoshiji Yamada; Miki Yamada; Noriko Sato; Masaaki Muramatsu; Masashi Tanaka; Yoko Irukayama-Tomobe; Yuki C Saito; Takeshi Sakurai; Masakazu Hayashida; Haruhiko Sugimura; Kazutaka Ikeda
Journal:  Mol Brain       Date:  2015-08-20       Impact factor: 4.041

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.